Additionally, they propose a potential solution by introducing the ferroptosis inducer JKE-1674, a highly selective and stable GPX4 inhibitor that demonstrated selective induction of ferroptosis and lipid peroxidation in prostate cancer cells compared to normal-like prostate epithelial cells, suggesting the feasibility of ferroptosis induction as a promising cancer therapy for RB1-deficient malignancies. This evidence concerns the gene RB1 and prostate cancer.